A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination TherapyReportar como inadecuado


A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy


A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

College of Chemical Engineering, Huaqiao University, Xiamen 361021, China

2

Institute of Pharmaceutical Engineering, Huaqiao University, Xiamen 361021, China

3

Fujian Provincial Key Laboratory of Biochemical Technology, Huaqiao University, Xiamen 361021, China





*

Author to whom correspondence should be addressed.



Academic Editor: Jung Ho Je

Abstract To minimize the non-specific toxicity of drug combination during cancer therapy, we prepared a new system synthesized from bacteria to deliver the anticancer drugs cytosine arabinoside Ara-C and daunorubicin DNR. In this study, we selected genipin GP and poly-l-glutamic acid PLGA as dual crosslinkers. Herewith, we demonstrated the preparation, characterization and in vitro antitumor effects of Ara-C and DNR loaded GP-PLGA-modified bacterial magnetosomes BMs ADBMs-P. The results show that this new system is stable and exhibits optimal drug-loading properties. The average diameters of BMs and ADBMs-P were 42.0 ± 8.6 nm and 65.5 ± 8.9 nm, respectively, and the zeta potential of ADBMs-P −42.0 ± 6.4 mV was significantly less than that of BMs −28.6 ± 7.6 mV. The optimal encapsulation efficiency and drug loading of Ara-C were 68.4% ± 9.4% and 32.4% ± 2.9%, respectively, and those of DNR were 36.1% ± 2.5% and 17.9% ± 1.6%. Interestingly, this system also exhibits long-term release behaviour sequentially, without an initial burst release. The Ara-C drug continued to release about 85% within 40 days, while DNR release lasted only for 13 days. Moreover, similar to free drugs, ADBMs-Ps are strongly cytotoxic to cancer cells in vitro HL-60 cells, with the inhibition rate approximately 96%. This study reveals that this new system has a potential for drug delivery application in the future, especially for combination therapy. View Full-Text

Keywords: magnetosomes; natural carrier; drug combination therapy; dual crosslinkers magnetosomes; natural carrier; drug combination therapy; dual crosslinkers





Autor: Ruimin Long 1,3, Yuangang Liu 1,2,3,* , Qinglei Dai 1, Shibin Wang 1,2,3, Qiongjia Deng 1 and Xia Zhou 1

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados